MARLBOROUGH, Mass. — Boston Scientific Corporation (NYSE: BSX) announced today that Dan Brennan, the company’s longtime executive vice president and chief financial officer, will retire after nearly 30 years with the medical device giant. Brennan will officially step down from the CFO role at the end of June but will remain with the company as a senior advisor through early October to support the leadership transition.
Brennan’s departure marks the end of a significant chapter for Boston Scientific, where he played a key role in shaping the company’s financial strategy and performance. Since taking over as CFO in 2014, Brennan has overseen a period of consistent financial growth and strategic investment. He has also been instrumental in cultivating the company’s values and culture, as well as developing financial talent across the organization.
“I thank Dan for his incredible leadership and tremendous contributions to Boston Scientific,” said Mike Mahoney, chairman and CEO of Boston Scientific. “Dan has been central to transforming our financial performance and guiding key investment opportunities. His leadership has helped establish the strong financial foundation and culture that define our company today.”
The company has named Jon Monson, currently senior vice president of investor relations, as Brennan’s successor. Monson will assume the role of executive vice president and CFO effective June 30, 2025, and will report directly to Mahoney. Monson and Brennan will work closely together over the next two months to ensure a seamless transition.
As CFO, Monson will oversee Boston Scientific’s global finance functions, including controllership, internal audit, corporate finance, treasury, tax, investor relations, and business development. He will also be responsible for driving talent development across the company’s global finance organization.
“Jon is a proven leader known for his strategic thinking, thoughtful leadership, and commitment to innovation,” Mahoney said. “With more than 25 years at Boston Scientific, he brings extensive financial expertise and experience across many areas of the company that will serve him well in his new role.”
Monson’s career at Boston Scientific includes five years as global controller and chief accounting officer, where he helped guide the company through financially turbulent times, including the challenges presented by the COVID-19 pandemic. Prior to that, he spent four years as vice president and controller of the company’s Urology business. A certified public accountant, Monson holds a bachelor’s degree in economics and accounting from the College of the Holy Cross.
With this leadership transition, Boston Scientific is positioning itself to maintain financial stability and continue driving growth as it advances its global healthcare portfolio.
